P Pharming Group NV
P
Suletud
0.906 3.42
Ülevaade
Aktsiahinna muutus
24h
Min
0.867
Max
0.909
Sissetulek | -10M -5.1M |
|---|---|
Müük | -36M 71M |
P/E Sektori keskmine | 56.5 64.641 |
Aktsiakasum | -0.006 |
Kasumimarginaal | -7.196 |
Töötajad | 407 |
EBITDA | -4.8M -2.1M |
Turukapital | -210M 798M |
|---|---|
Eelmine avamishind | -2.51 |
Eelmine sulgemishind | 0.906 |
Pharming Group NV Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pharming Group NV Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.